Trevi Therapeutics Inc (NASDAQ: TRVI) on Friday, plunged -5.21% from the previous trading day, before settling in for the closing price of $4.03. Within the past 52 weeks, TRVI’s price has moved between $1.27 and $4.68.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -66.76%. With a float of $52.99 million, this company’s outstanding shares have now reached $75.45 million.
The extent of productivity of a business whose workforce counts for 25 workers is very important to gauge. In terms of profitability, gross margin is 38.64%, operating margin of -27394.89%, and the pretax margin is -25196.59%.
Trevi Therapeutics Inc (TRVI) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Trevi Therapeutics Inc is 40.71%, while institutional ownership is 35.35%. The most recent insider transaction that took place on Sep 06 ’24, was worth 12,784. In this transaction President & CEO of this company sold 4,219 shares at a rate of $3.03, taking the stock ownership to the 213,313 shares. Before that another transaction happened on Sep 09 ’24, when Company’s President & CEO sold 1,840 for $3.04, making the entire transaction worth $5,587. This insider now owns 213,313 shares in total.
Trevi Therapeutics Inc (TRVI) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -66.76% per share during the next fiscal year.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Trevi Therapeutics Inc (TRVI) is currently performing well based on its current performance indicators. A quick ratio of 7.38 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.49 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
The latest stats from [Trevi Therapeutics Inc, TRVI] show that its last 5-days average volume of 0.57 million was inferior to 0.7 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 8.79%. Additionally, its Average True Range was 0.35.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 62.93%, which indicates a significant increase from 4.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.17% in the past 14 days, which was lower than the 89.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.35, while its 200-day Moving Average is $3.03. Now, the first resistance to watch is $4.00. This is followed by the second major resistance level at $4.18. The third major resistance level sits at $4.29. If the price goes on to break the first support level at $3.71, it is likely to go to the next support level at $3.60. The third support level lies at $3.42 if the price breaches the second support level.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
Market capitalization of the company is 341.38 million based on 76,866K outstanding shares. Right now, sales total 0 K and income totals -29,070 K. The company made 0 K in profit during its latest quarter, and -13,240 K in sales during its previous quarter.
